Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid

0533415 - BTÚ 2021 RIV US eng J - Článek v odborném periodiku
Liu, Y. - Pang, Y. - Zhu, B. - Uher, O. - Caisova, V. - Huynh, T.-T. - Taieb, D. - Váňová-Hadrava, Kateřina - Ghayee, H. K. - Neužil, Jiří - Levine, M. - Yang, Ch. - Pacak, K.
Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid.
Clinical Cancer Research. Roč. 26, č. 14 (2020), s. 3868-3880. ISSN 1078-0432. E-ISSN 1557-3265
Grant CEP: GA ČR(CZ) GA18-10832S; GA MŠMT(CZ) ED1.1.00/02.0109
Institucionální podpora: RVO:86652036
Klíčová slova: succinate-dehydrogenase * complex-ii * inhibitor sunitinib * hydrogen-peroxide
Obor OECD: Oncology
Impakt faktor: 12.531, rok: 2020
Způsob publikování: Open access
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443979/

Purpose: Pheochromocytomas and paragangliomas ( PCPG) are usually benign neuroendocrine tumors. However, PCPGs with mutations in the succinate dehydrogenase B subunit (SDHB) have a poor prognosis and frequently develop metastatic lesions. SDHB-mutated PCPGs exhibit dysregulation in oxygen metabolic pathways, including pseudohypoxia and formation of reactive oxygen species, suggesting that targeting the redox balance pathway could be a potential therapeutic approach.
Trvalý link: http://hdl.handle.net/11104/0311808